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Objective: Myocardial infarctions constitute a major factor contributing to non-natural mortality world-wide. Clinical
trials ofmyocardial regenerative therapy, currently pursued by cardiac surgeons, involve administration of stem cells
into the hearts of patients suffering from myocardial infarctions. Unfortunately, surgical acquisition of these cells
from bone marrow or heart is traumatic, retention of these cells to sites of therapeutic interventions is low, and
directed differentiation of these cells in situ into cardiomyocytes is difficult. The specific aims of this work were: (1)
to generate autologous, human, pluripotent, induced stem cells (ahiPSCs) from the peripheral blood of the patients
suffering myocardial infarctions; (2) to bioengineer heterospecific tetravalent antibodies (htAbs) and use them for
recruitment of the ahiPSCs to infarcted myocardium; (3) to initiate in situ directed cardiomyogenesis of the ahiPSCs
retained to infarcted myocardium.
Methods: Peripheral blood was drawn from six patients scheduled for heart transplants. Mononuclear cells were
isolated and reprogrammed, with plasmids carrying six genes (NANOG, POU5F1, SOX2, KLF4, LIN28A, MYC), to yield
the ahiPSCs. Cardiac tissues were excised from the injured hearts of the patients, who received transplants during
orthotopic surgery. These tissues were used to prepare in vitro model of stem cell therapy of infarcted myocardium.
The htAbs were bioengineered, which simultaneously targeted receptors displayed on pluripotent stem cells
(SSEA-4, SSEA-3, TRA-1-60, TRA-1-81) and proteins of myocardial sarcomeres (myosin, α-actinin, actin, titin). They
were used to bridge the ahiPSCs to the infarcted myocardium. The retained ahiPSCs were directed with bone
morphogenetic proteins and nicotinamides to differentiate towards myocardial lineage.
Results: The patients’ mononuclear cells were efficiently reprogrammed into the ahiPSCs. These ahiPSCs were
administered to infarcted myocardium in in vitro models. They were recruited to and retained at the treated
myocardium with higher efficacy and specificity, if were preceded the htAbs, than with isotype antibodies or plain
buffers. The retained cells differentiated into cardiomyocytes.
Conclusions: The proof of concept has been attained, for reprogramming the patients’ blood mononuclear cells
(PBMCs) into the ahiPSCs, recruiting these cells to infarcted myocardium, and initiating their cardiomyogenesis. This
novel strategy is ready to support the ongoing clinical trials aimed at regeneration of infarcted myocardium.
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Myocardial infarctions (MI) constituted a major factor con-
tributing to non-natural mortality world-wide in 2012 [1,2].
Causes of myocardial infarctions are complex, but all
result in cessation of blood supply to and necrosis of
myocardium. Subsequently, some of the sarcomeric
proteins are quickly and freely released from the infarcted
myocardium into blood circulation. They become diagnos-
tic biomarkers of myocardial damage detected with anti-
bodies in blood and urine, e.g., antibodies against troponin
or myosin light chains used for enzyme-linked immuno-
sorbent assay (ELISA). The remaining cardiac proteins are
retained within sarcomeres, but are exposed to constitu-
ents of blood through the damaged endothelia and sarco-
lemmas. They become landmarks of location and extent
of the cardiac damage determined by antibody-guided
contrast agents for molecular imaging, e.g., antibodies
to myosin heavy chains modified with radionuclide for
positron emission tomography (PET) or modified with
superparamagnetic clusters for magnetic resonance imaging
(MRI). Immediate surgical revascularization is critical to
prevent progression of myocardial injury, which otherwise
may result in heart failure and the patient’s death [3-5].
Clinical trials of myocardial regenerative therapy,
currently pursued by cardiac surgeons, involve admin-
istration of cells, which have ability to differentiate or
trans-differentiate into cardiac muscle or endothelia,
into the hearts of patients suffering myocardial infarctions
[5-8]. The rationale for this strategy is to replace necrotic
cardiac muscle with new, functional cells. Main routes
of delivery involve: myocardial injections, blood infusions,
or pericardial patches [5-9]. However, recruitment and
retention of these cells to the sites of therapeutic interven-
tions is so low, that only 1-3% of the infused and 6-12% of
the injected cells are detected at the sites of therapeutic
deliveries 2 weeks later [5-9]. This translates into poor and
inconsistent therapeutic effects. Therefore, resolving this
problem has been recognized as the most critical priority to
achieve progress in stem cell-based cardiac therapy [5-11].
Attempts to compensate for the losses in administered cells
by increasing their numbers are limited by the injections’
volumes [9]. Therefore, the novel biotechnology has been
developed to improve recruitment and retention of thera-
peutic stem cells with the aid of bioengineered, heterospeci-
fic, polyvalent antibodies (htAbs), which efficiently anchor
more than 90% of administered cells to the regenerated
myocardium [10,11]. These antibodies are uniquely specific
for the human stem cell stage specific antigens resulting inacquisition of the data that are clinically relevant and ready
for streamlining into clinical trials. This feature is essen-
tial, since the biomarkers of human stem cells are different,
expressed at different stages of differentiation, or com-
pletely absent, than those of non- humans. The htAbs
demonstrate exquisite specificity and affinity, which
after their fluorescent, elemental, or magnetic modifi-
cation; ensure selection of batches of pluripotent stem
cells with high purity and viability, as well as tracking
these cells in vivo [12-18].
Human, bone marrow cells are most commonly used
in the ongoing clinical trials of cells-based cardiac regener-
ation [5-10]. Cardiac stem cells have also been recently in-
troduced into the clinical trials [5-9]. Human induced
pluripotent stem cells, which are reprogrammed from
bone marrow, heart, skin, or peripheral blood are vigor-
ously studied [11,19-27]. Alternatively, cells differentiating
towards cardiac cells are generated by directed lineage re-
programming [10,28-38].
In general, the main problem with the therapeutic
efficacy of cells-based therapy is still the recruitment and
retention of the administered stem cells to the sites of the
intended therapeutic interventions [5-9,39,40]. Moreover,
the challenge for using stem cells in regenerative medicine
is to assure their differentiation or trans-differentiation
towards the desired lineage and functional integration
with the host tissue. Finally, the most serious problem
with streamlining the pluripotent stem cells into clinics
is the risk of their tumorigenic transformation [41-50].
In this realm, the specific aims of this work were: (1) to
generate autologous, human, pluripotent, induced stem
cells (ahiPSCs) from the peripheral blood of the patients
suffering myocardial infarctions; (2) to bioengineer hetero-
specific antibodies (htAbs) and use them for recruitment
of the ahiPSCs to the infarcted myocardium; (3) to initiate
in situ directed cardiomyogenesis of the ahiPSCs retained
to infarcted myocardium.
Methods
Concept for recruitment and retention of pluripotent
induced stem cells to infarcted myocardium with
bioengineered antibodies
Principles of a novel strategy, for anchoring autologous,
human, pluripotent, induced stem cells (autologous hiPSCs
or ahiPSCs) to sarcomeres of infarcted myocardium, with
the aid of the bioengineered, heterospecific tetravalent anti-
bodies (htAbs), are illustrated (Figure 1). These principles
are applicable to an in vitro model of regenerative therapy
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into clinical trials in vivo. Genetically engineered, monova-
lent synthetic nano-antibodies are against pluripotent stem
cells’ biomarkers: SSEA-4, SSEA-3, TRA-1-60, TRA-1-81,
and simultaneously against sarcomeric molecules: myosin,
α- actinin, actin, and titin. Each nano-antibody is modified
to carry a single biotin group at the carboxyl terminus. One
at a time, these antibodies are docked into avidin. This way
they form sequentially batches of mono-, bi-, tri-, or tetra-
valent antibodies.
Our novel “recruit-and-retain” therapeutic strategy con-
sists of four phases. First, htAbs are spiked into the solution
flowing over sarcomeres (A). The htAbs are recruited onto
the sarcomeres through their anti-myosin, anti-α-actinin,
anti-actin, and anti-titin domains. (B). After clearing out
unbound htAbs, the solution is spiked with SSEA-4, SSEA-
3, TRA-1-81, and TRA-1-60 displaying autologous hiPSCs
(ahiPSCs) (C). The ahiPSCs dock into the anti-SSEA-4,
anti-SSEA-3, anti-TRA-1-81, and anti-TRA-1-60 domains
of the htAbs, which remain anchored onto the sarcomeres
(D). Thereafter, these anchored autologous, human, pluri-
potent, induced stem cells are subjected to directed differ-
entiation towards the heart regenerating cardiomyocytes.
Patients
All samples were obtained in accordance with the
Declaration of Helsinki with the Institutional Review
Boards’Approval and with the Patients’ Informed Consent.
The cohort consisted of 3 men and 3 women, who after
suffering from multiple infarctions, were recommended to
receive orthotopic heart transplants and agreed to using
infarcted myocardium for research.Figure 1 Concept for recruitment of human pluripotent stem cells to
myosin (in A-band), α-actinin (in Z-line), actin (I-band), titin (with various d
pluripotent stem cells (ahiPSCs) display on their surfaces biomarkers: SSEA
(htAbs) target the sarcomeric proteins and simultaneously the pluripotent
(A – injection of htAbs, B – anchoring to sarcomeres; C – injection of ahiP
bonds between myosin, α-actinin and TRA-1-60, SSEA-4 are shown.Peripheral blood mononuclear cells
Small volumes of blood (1-10 ml) were drawn from these
patients according to standard clinical laboratory practices
into heparin tubes (green tops). Blood was diluted 2-4x
with physiological buffered saline (PBS) without calcium
and magnesium in sterile tubes and layered over Ficoll.
That followed by centrifugation in swinging bucket rotor
at 400xg, 22°C for 30 min. Plasma layers were transferred
to separate tubes. Buffy coats containing PBMCs were
gently aspirated, suspended in fresh PBS and spun at
350xg, 22°C for 10 min. After discarding supernatants, the
cells were suspended in PBS again and spun down at
200xg, 22°C for 10 min. [14,15,18-20]. Approximately 5
million of mononuclear cells were isolated from 10 ml
of blood. These cells were immediately processed as
described below. Alternatively, they were suspended in
PBS supplemented with 5% starch, 5% DMSO, 30% hu-
man serum for 15 min. on ice and cryoimmobilized in the
programmable freezer (the freezer was designed and built
based upon the NSF funds granted to Dr M. Malecki,
Principal Investigator) at 1°C/min down to −30°C at 1°C/
min, rapid cooling between down to −70°C at 30°C/min,
and the final phase down to −196°C at 3°C/min.
Human autologous pluripotent induced stem cells
Mononuclear cells from peripheral blood were repro-
grammed into human, autologous, pluripotent, induced
stem cells (autologous hiPSCs or ahiPSCs) by transduction
with plasmids in biotags carrying six genes OCT4, SOX2,
NANOG, LIN28, KLF4, MYC in media supplemented
with 1 mM valproic acid (VPA), 1 mM antibody to trans-
forming growth factor-β receptor 1 (anti-TGFR1). Thesarcomeres of infarcted myocardium. Sarcomeric proteins include:
omains stretched between Z-lines). Autologous human induced
-4, TRA-1-60, SSEA-3, TRA-1-81. Heterospecific tetravalent antibodies
stem cells’ biomarkers. Four phases of recruitment are shown:
SCs; D – anchoring of ahiPSCs). For clarity of the presentation, only
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manently tagged the stem cells. Sustained cultures of
the autologous hiPSCs and human embryonic stem cells
(hESCs) were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with knockout serum
replacement (KOSR), mercaptoethanol, glutamine, nones-
sential amino acids, fibroblast growth factor 2 (FGF2). They
were subjected to three rounds of enrichment by magnetic
or fluorescent activated cell sorting to attain > 99% purity.
That followed by 50–100 fold clonal expansion and long
term cultures in CelliGen BLU Single-Use, Stirred-Tanks
Bioreactors (New Brunswick, NJ, USA) with the batch media
feeding, impeller set at 100 rpm, and all USP Class VI and
animal component free materials, thus GMP compliant, as
described [14-16,26-28]. Pluripotency of these cells was de-
termined by detecting cell surface display of biomarkers and
ability to form embryoid bodies (EBs). Cell surface displayed
biomarkers were quantified and isolated by fluorescence
and magnetic activated sorting after labeling with fluores-
cent and superparamagnetic antibodies’ (respectively)
against: SSEA-4, SSEA-3, TRA-1-60, TRA-1-81, which
were thoroughly characterized [17,18].
Ability to form the EBs was determined by transferring
onto poly(2-hydroxyethyl-methacrylate)-coated dishes in
media 20% knockout serum replacement (Invitrogen,
Carlsbad, CA, USA), L-glutamine, nonessential amino acids,
mercaptoethanol, penicillin, streptomycin in DMEM/F12
exchanged 3x for a week. After a week, the individual
EBs were transferred into matrigel-coated dishes in the
same media for another week. Differentiation was de-
termined by measuring transcripts by qPCR and prod-
ucts by immunocytochemistry for genes unique for the
three main germ layers. Quantitative analysis in situ of
differentiation kinetics was facilitated by labeling with
antibodies against myosin heavy chains, neurofilamentous
proteins, cytokeratins, adrenergic β1 receptors, acetylcho-
line receptors, and platelet endothelial cell adhesion
molecules, which were modified with: (1) superparamagnetic
clusters, so that they were affecting relaxivities of the la-
beled samples in NMRS; (2) elemental tags, so that they
were changing the scintillation counts radiating from the
labeled samples in EDXS or XRFS [15]. Both approaches
save sample preparation times, are much safer, and easier
to implement for academic laboratories.
Cardiac tissues
Cardiac tissues were sampled from the infarcted hearts,
while the transplants’ recipients were undergoing ortho-
topic procedures. The tissues were transferred into the
University of Wisconsin solution immediately after the
release from thorax. They were processed within 4 h or
cryoimmobilized for storage in liquid nitrogen at −196°C
indefinitely (the freezer was designed and built based upon
the NSF funds granted to Dr M. Malecki, PI).Immediate processing involved five routes. (1) Native
myofibrils were prepared to retain antigenicity of sar-
comeric proteins. Strips of cardiac muscle tissue were
immersed in myofibril buffered solution: 75 mM KCI,
10 mM Tris pH6.8, 2 mM EGTA, 2 mM MgCl2, 0.1 mM
PMSF, 0.1% TritonX-100 and homogenized in Polytron
(Brinkman Instruments Co., Westbury, NY, USA) and
Teflon glass homogenizer. That followed by three cycles
of spinning and suspending. They were immediately used
to assemble models of infarcted myocardium inside en-
vironmental chambers or infused with the fresh myo-
fibril buffered solution containing 50% glycerol and
frozen. (2) Cryosections were cut from the cardiac tissues,
which were rapidly cryoimmobilized in the HPM 010
(Balzers, Lichtenstein, EU) for retaining life-like anti-
genicity. The frozen muscles were either sectioned directly
in frozen hydrated state or cryo-substituted, infused
with 2.3 M sucrose, refrozen, then sectioned (Leica, Vienna,
A, EU). (3) The frozen tissues were crushed, homogenized,
and lyophilized to be used, after thawing and dialysis,
for immunoblotting or supplementing cell cultures. (4) The
cardiac tissues were homogenized and dissociated in de-
naturing sample solution: 1% sodium-dodecylsulafate,
10% glycerol, 10 mM Tris-Cl, pH 6.8, 1 mM ethylene-
diamine tetraacetic acid, with or without reducing agents
2 mg/ml dithiothreitol (DTT) or 2- mercaptoethanol, colored
with ~0.05 mg/ml bromophenol blue. (5) Cell cultures were
initiated from the cardiac tissues and grown in incubators
maintaining 37°C, 10% CO2, and saturated humidity.
Cryoimmobilization was accomplished in the program-
mable freezer (the freezer was designed and built based
upon the NSF funds granted to Dr M. Malecki, PI) at 1°C/
min down to −30°C at 1°C/min down, rapid cooling down
to −70°C at 30°C/min, and the final phase down to −196°C
at 3°C/min. It was conducted after equilibrating the tissue
with 5% starch, 5%DMSO, 30% human serum in PBS for
15 min.
All samples were examined by multiphoton fluores-
cence spectroscopy (MPFS), immunoblotting (IB), flow
cytometry (FCM), quantitative reverse transcription and
polymerase chain reaction (qRTPCR), nuclear magnetic
resonance spectroscopy (NMRS), energy dispersive x-ray
spectroscopy (EDXS), and x-ray fluorescence spectroscopy
(XRFS) as described below.
Bioengineering of heterospecific tetravalent
antibodies (htAbs)
Heterospecific tetravalent antibodies were bioengineered
using coding sequences from two groups of the nano-
antibodies developed earlier, which were targeting: pluri-
potency biomarkers and sarcomeric proteins as described
[15-18,39,40].
The B cells were collected from the patients suffer-
ing myocardial infarctions, as well as from the patients
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The mRNA was isolated (Trizol, MRC, Cincinnati, OH,
USA) and reverse transcribed to cDNA (Cell-to-DNA,
Qiagen, San Diego, CA). These new sequences were
assembled into the libraries of anti-cancer-antibodies
(ACA) coding sequences and anti-heart antibodies (AHA).
The cds, after insertion into the plasmids containing
chelates’ harboring coding sequences under the CMV
promoters and terminated with polyA, were propagated
and expressed in human myelomas.
Complementarity determining regions (CDR) and frame-
work regions (FWR) were re-engineered by sequence
shuffling, while expressed on human myelomas. The native
SSEA-4, SSEA-3, TRA-1-60, TRA-1-81, CD-45, CD-34,
CD-19, CD-20, myosin, actin, titin, and α-actinin were
purified by immunoprecipitation with monoclonal anti-
bodies, which followed by their modification with biotin,
digoxigenin, tetramethylrhodamine, or fluorescein. They
were anchored onto anti-biotin, anti-dig, anti-TMR, or
anti-FITC saturated pans and served as baits for selection
of the antibodies clones from the aforementioned libraries.
The chelates were saturated with Ni, Co, Gd, Fe, Tb, and
Eu as described. The specificity and sensitivity were de-
termined based upon elemental compositions with EELS
(Zeiss, Oberkochen, D, EU), EDXS (Noran, Middleton,
WI, USA), or XRFS (Bruker AXS, Fitchburg, WI, USA).
The fluorescent properties were measured with the RF-
5301PC spectrofluorometer (Shimadzu, Tokyo, Japan).
The specificity and sensitivity of the antibodies were
tested with the EELS and EDXS. The magnetic relaxivities
were measured on the DMX 400 WB or AVANCE II NMR
spectrometers (Bruker Optics, Dallas, TX, USA). The
monoclonal antibodies for these antigens served as the
positive controls, and antibodies towards 6His, DOTA,
TETA, and DTPA served as the negative controls.
For preparing tetravalent antibodies, the first batch
of monovalent antibodies was sprayed from the air-
brush with a single pulse over the pan filled with the
0.01-0.001 mg/mL recombinant avidin (rA) in PIPES
buffer in a saturated humidity chamber maintained at
room temperature. Upon completion of binding, the
fractions of resulting solution were separated by the
size exclusion chromatography on high pressure liquid
chromatography columns (HPLC) (Pharmacia, S, EU)
with 0.5 mL/min flow at 30 bar pressure. The fractions
were collected on the fraction collector equipped with the
280 nm sensor (Pharmacia, S, EU). The fractions detected
at the ~95kD peak and containing rA linked with the
single monovalent antibody were pooled together and
filled a new pan. That was uniformly sprayed over with
the new antibodies. The first peak of rA saturated with
four monovalent antibodies was used for specific blocking
on competitive assays. The procedure was repeated for
all antibodies, one at a time, in a random order. In thefinal separation tetravalent antibodies were collected at
the peak of ~170 kDa. The system was calibrated using
classic IgG, BSA, avidin, Fab, and myoglobin as the stan-
dards. Specificity and sensitivity of the bioengineered
tetravalent antibodies were tested by immunoblotting
(IB), labeling and multiphoton fluorescence spectroscopy
(MPFS), EDXS, and EELS.
Flow cytometry (FCM), Fluorescently activated cell sorting
(FACS), Multiphoton Fluorescence Spectroscopy (MPFS)
For flow cytometry (FCM), fluorescent activated cell sorting
(FACS) and magnetic activated cell sorting (MACS)
the cells were thoroughly prepared as single cell suspen-
sions by short treatment with the PIPES buffered DNase,
RNase, trypsin, collagenase, or dispase II (0.5 units/
mg). These preparations included cell clusters and embry-
oid bodies. Moreover, apoptotic cells were removed
with the anti-PS and dead cells with the anti-DNA
antibodies. The enriched populations of the cells were
labeled with the anti-TRA-1-60, anti-TRA-1-81, anti-
SSEA-3, and anti-SSEA-4 fluorescent antibodies, which
were thoroughly characterized previously [17,18].
They were quantified with the Calibur, Vantage SE,
or Aria (Becton-Dickinson, Franklin Lakes, NJ, USA)
or the FC500 (Beckman- Coulter, Brea, CA, USA). The
fluorescently labeled cells were imaged with the Axiovert
(Zeiss, Oberkochen, D, EU) equipped with the Enterprise
argon ion (457 nm, 488 nm, 529 nm lines) and ultraviolet
(UV) (364 nm line) lasers; Odyssey XL digital video-rate
confocal laser scanning imaging system operated up to 240
frames/s under control of Intervision software (Noran,
Madison, WI, USA), and the Diaphot (Nikon, Tokyo, Japan)
equipped with the Microlase diode-pumped Nd:YLF solid
state laser (1048 nm line), the pulse compressor with the
pulses’ rate 300 fs at 120 MHz and the MRC600 scanning
system under control of Comos software (the multi-photon
fluorescence station built based upon the NIH funds for Dr
J. White, PI). Deconvolution of images was done on the
Indy workstation (Silicon Graphics, Fremont, CA, USA).
Nuclear magnetic resonance spectroscopy (NMRS)
Magnetic activated cell sorting (MACS)
The cells were labeled for positive selection with the super-
paramagnetic antibodies targeting TRA-1-60, TRA-1-81,
SSEA-3, and SSEA-4, and for the negative selection target-
ing CD45, CD34, dsDNA, and PS, while suspended in the
physiological buffer supplemented with serum and glucose.
The small aliquots were dispensed into the magnetism-free
NMR tubes (Shigemi, Tokyo, Japan). The relaxation times
T1 were measured in resonance to the applied FLAIR pulse
sequences on the NMR spectrometers: DMX 400 WB
or AVANCE II NMR (Bruker, Billerica, MA) or the Signa
clinical scanners (GE, Milwaukee, WI, USA). The superpar-
amagnetic antibodies were also used to isolate the labeled
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above 99.5% of purity (the sorter designed and built based
upon the NSF funds for Dr M. Malecki, PI).
Electron energy loss spectroscopy (EELS), Energy
dispersive x-ray spectroscopy (EDXS), X-ray reflection
fluorescence spectroscopy (XRFS)
The samples, which were cryo-immobilized, presented
the life-like supramolecular organization. Molecular
imaging was pursued as described. The field emission,
scanning transmission, electron microscope FESTEM
HB501 (Vacuum Generators, Kirkland, WA, USA) was
equipped with the energy dispersive x-ray spectrometer
(EDXS) (Noran, Middleton, WI, USA) and post- col-
umn electron energy loss spectrometer (EELS) (Gatan,
Pleasanton, CA). The cryo-energy filtering transmission
electron microscope 912 Omega was equipped with
the in-column, electron energy loss spectrometer (EELS)
(Zeiss, Oberkochen, D, EU). The cryo-energy filtering
transmission electron microscopes 410 and 430 Phillips
were equipped with the post-column, electron energy loss
spectrometers (EELS) (Noran, Middleton, WI, USA). The
field emission, scanning electron microscope SEM1530
(Zeiss, Oberkochen, D, EU) was equipped with the energy
dispersive x-ray spectrometer (EDXS) (Noran, Middleton,
WI, USA). The field emission, scanning electron micro-
scope 3400 was equipped with the energy dispersive
x-ray spectrometer (EDXS) (Hitachi, Tokyo, Japan). The
images and spectra were acquired using the ccd camera
operating under the image acquisition and processing
software (SIS, Herzogenrath, D, EU or Emispec Systems,
Tempe, AZ, USA).
In the XRFS study, the ICP standard of 1000 mg/l of
mono-element Gallium (CPI International, Denver, CO,
USA) was added to 500 microL of each sample to the final
concentration of 10 mg/l. The data were generated from the
S2 Picofox XRF spectrometer equipped with a molybdenum
(Mo) X-ray target and the Peltier cooled Xflash Silicon Drift
Detector (Bruker AXS, Fitchburg, WI, USA). Scan times
ranged up to 1000 seconds. The automatic sample changer,
which can hold up to 25 samples, was also used along with
the SPECTRA 7 software for the instrument control, data
collection, and analysis (Bruker AXS, Fitchburg, WI, USA).
Immunoblotting (IB)
The cells and tissues were either frozen in liquid nitrogen,
crushed, and thawed or disintegrated with ultrasonicator
(Branson Ultrasonic, Danbury, CT, USA) within the sample
buffers for native protein analysis. They were stored in
liquid nitrogen or electrophoresed in the native buffer
(Invitrogen, Carlsbad, CA, USA). They were vacuum or
electro-transferred onto the PVDF membranes (Amersham,
Buckinghamshire, UK, EU). The membranes carrying the
transferred proteins were soaked within human serum andlabeled with the antibodies. The samples of purified cardiac
muscle myosin, actin, α-actinin, titin served as the controls.
The commercially available monoclonal antibodies
against myosin, actin, α-actinin, titin, SSEA-3, SSEA-4,
TRA-1-60, TRA-1-81, CD34, and CD45 served as the con-
trols. The images of the blots were acquired and quantified
with Fluoroimager (Molecular Dynamics, Sunnyvale, CA,
USA) or Storm 840 (Amersham, Buckinghamshire, UK,
EU). The levels of the gene expression products were also
calculated, as the ratio between the protein concentration
in the examined patient’s cells and the controls.
Quantitative reverse transcription and polymerase chain
reaction (qRTPCR)
Total RNA was isolated with TRIzol (MRC, Cincinnati,
OH, USA). In addition to the patients’ cardiac tissues, the
fibroblasts, peripheral blood cells, and bone marrow cells
were processed. The cultured fibroblasts (IMR90), human
embryonic stem cells (H1, H9), and blood from the healthy
volunteers served as the controls. For all, RNA served as
the template to generate cDNA through reverse transcrip-
tion using random hexamers and reverse transcriptase
(ABI, Foster City, CA, USA). The primers’ sequences and
cycling settings were published [14-18]. The transcripts
for GAPDH and actin served as the internal controls
(ABI, Foster City, CA, USA). They were synthesized on
the 380A DNA Synthesizer (ABI, Foster City, CA, USA).
The PCR reactions were carried using the mix of the
cDNA, the synthesized primers, dNTPs, and Taq DNA
polymerase (Hoffmann–La Roche, Basel, H) on the
Robocycler (Stratagene, San Diego, CA, USA), Mastercycler
(Eppendorf, Hamburg, D, EU), or 7500, 7900 systems
(ABI, Foster City, CA, USA). The images of the gels were
acquired and quantified with Fluoroimager (Molecular
Dynamics, Sunnyvale, CA, USA) or Storm 840 (Amersham,
Buckinghamshire, UK, EU). The levels of the transcripts
were all normalized against GAPDH or actin. Thereafter,
they were calculated as the ratios between the transcripts’
concentration in the examined patient’s cells versus the
cells from the healthy control tissues and cultures.
Targeting and retention of pluripotent stem cells to
cardiac sarcomeres
Simulation of the therapeutic procedure for delivering of
the stem cells to the infarcted sarcomeres was based
upon the models of the myocardial infarctions prepared
in the environmental chambers. The bottoms of these
chambers were covered with firmly attached native myo-
fibrils or sectioned cardiac infarcted tissues. Alterna-
tively, the human artery endothelial cells were grown as
monolayers at the bottom of the chambers to imitate the
coronary artery walls. In both cases the sarcomeres were
exposed to the over-flowing solution as they would be in
the myocardial infarctions. The buffered culture medium
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peristaltic pump (Flowrox, Linthicum, MD, USA). The
chambers were tightly sealed and connected with the envir-
onmental incubator through flexible Tygon hoses. They as-
sured maintaining the myofibrils and cells at 37°C, pH 7.3,
120/80 mmHg, and 330 mOsm. Under continuous flow,
the buffer was spiked with the htAbs against myosin, acti-
nin, titin, and actin. After, 30 minutes, the circulating htAb
solution was replaced with the new, htAb-free solution.
Thereafter, the induced pluripotent stem cells were spiked
in. At various time intervals, the flow was stopped and the
number of cells evaluated based upon quantifying changing
ratios in relaxivities or x-ray scintillations. These quantifica-
tions were possible due to the superparamagnetic or elem-
ental tags carried by the cells [14-18].
Directed cardiomyogenesis of pluripotent stem cells
Pluripotent stem cells were anchored to sarcomeres in the
environmental chambers described above. The circulating
solution consisted of Dulbecco’s Modified Eagle’s Medium
supplemented with 20% human serum, 10% lyophilized
cardiac tissue, while maintained at 37°C and controlled O2/
CO2/N2 ratios. For triggering cardiomyogenesis that solu-
tion was supplemented with 10 ng/ml bone morphogenetic
protein (BMP), 10 mM nicotinamide (NAM), and antibodies
10 ng/ml anti‐fibroblast growth factor receptor (anti-FGFR),
10 ng/ml anti- vascular endothelial growth factor receptor
(anti-VEGFR), 10 ng/ml anti-platelet derived growth factor
receptor (anti-PDGFR), which were preceded by 24 h
pre-treatment with media supplemented with 100 ng/ml
hrActivin A (Act) and 100 ng/ml hr-Wingless-related inte-
gration site gene product (Wnt3) (R&DS, Minneapolis, MN,
USA). Differentiation versus pluripotency was determined
on the 1st, 5th, and 12th day, by qRTPCR of transcripts for
genes: GATA4, MEF-2c, OCT4, NANOG [22,23].
Proliferation and differentiation of cells in embryoid bodies
Single cardiomyocytes were isolated from early (day 5–12)
and late (day 59–62) embryoid bodies. From contracting
embryoid bodies the single cardiomyocytes were cultured
in the media supplemented with 10 μM BrdU (Invitrogen,
Carlsbad, CA, USA). Cells were fixed in 4% formaldehyde,
permeabilized in 0.1% Triton X-100 and denatured in
2 mol/L HCL in PBS for 30 minutes at room temperature.
The cells were labeled with anti-BrdU, anti-dsDNA, and
anti-cardiac myosin synthetic antibodies described above
[39] which were modified with metal binding domains
chelating Tb, Gd, or Eu. The ratios of BrdU positive cells
were calculated in relation to the number of nuclei of
cardiac myosin positive cells.
Statistical analysis
The statistical analysis and presentations were performed
using GraphPad Prism software (GraphPad Software, Inc,San Diego, CA, USA). All the data were acquired from at
least three independent runs of each patient’s samples. For
comparisons between two groups of data, the unpaired
t-test was applied and P calculated. The statistics were
calculated and presented as mean ± standard deviation
of the mean. The results were considered as statistically
significant for P < .05.
Results
Preservation of antigenicity and architecture in infarcted
myocardial sarcomeres
Preservation of structural integrity of sarcomeric architecture
in infarcted myocardium was determined with Zernicke’s
phase-contrast imaging of myofibrils (Figure 2). This
followed by analysis of the pixel density distribution.
The main framework of sarcomeres was preserved with
solid A-bands and clearly marked Z-lines. These structures
retained sharp edges indicative of complete absence of
proteolytic degradation.
Retention of antigenicity of sarcomeric proteins in
infarcted myocardium was validated by labeling with
tetravalent antibodies. Each antibody was specific for a
particular sarcomeric protein and was tagged with a
different fluorochrome. This facilitated multiple label-
ing. The images of the same myofibril, as that shown by
Zernicke’s phase contrast, were acquired by multiphoton
fluorescence spectroscopy. That facilitated correlations
between architecture and antigenicity. Multiple labels
were exquisitely specific to the main components of the
myocardial sarcomeres. Strong and specific glow after
labeling of cardiac myosin strictly coincided with the
A-bands (Figure 2B). The labeling was more prominent
near the M-line, co-localized with creatine kinase, due
to reduced steric hindrance. That was also the case at
the A-bands’ edges (Figure 2C). Strong fluorescence la-
beling of α-actinin sharply co-localized with the Z-line
(Figure 2D). That labeling was flanked by highlighted
elastic domains of titin in close proximity and on both
sides of the Z-line (Figure 2E). Labeling of cardiac actin
co-localized with the I-bands, which were intercalated
between the A-bands and Z-lines. All the samples were
run in triplicates. The images were representative for all
the patients’ samples studied.
Strong and specific immunolabeling of the sarcomeric
proteins confirmed excellent preservation of antigenicity
and molecular architecture, which were essential for
anchoring the htAbs upon them.
Human autologous pluripotent induced stem cells
Peripheral blood mononuclear cells (PBMCs) were trans-
fected with the plasmids DNA of OCT4, SOX2, NANOG,
LIN28, KLF4, MYC genes. This resulted in efficient re-
programming towards human, autologous, pluripotent,
induced stem cells (autologous hiPSCs) as documented
Figure 2 Molecular architecture of sarcomeres in infarcted myocardium. (A) Preservation of the myofibril structure was imaged by phase
contrast light microscopy (Z = Z-line; A = A-band). Underneath the image, there is the corresponding, quantified analysis of the spatial distribution
of the optical density (Y axis - relative units). It is a way to estimate sarcomers’ structural integrity. (B-E) Distribution of proteins was determined
with the htAbs carrying chelated atoms of exogenous elements and emitting specific spectra. Colors were assigned artificially. Underneath the
images, there are quantifications of spatial distribution of fluorescence intensity. Correlations between A and B-E determine, if the molecules
retain their positioning within the sarcomeres’ architecture. HFW: 4.8 μm. Pixel brightness compared between the specific labels and the back-
grounds during acquisition was accepted at the statistical significance P < .0001.
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determined by labeling with the htAbs targeting cell surface
displayed biomarkers, which were considered to be the
hallmarks of pluripotency: SSEA-4, SSEA-3, TRA-1-60,
TRA-1-81. The labeled autologous, human, induced
pluripotent, stem cells (ahiPSCs) were analyzed by
flow cytometry (Figure 3A-D). Their expression profiles
were highlighted as unique for pluripotent stem cells,
as validated by isotype controls. All samples were run in
triplicates and the ones shown are representative for all.
After that validation, batches of expressers were isolated by
magnetic and fluorescent activated cell sorting.
Pluripotency of the autologous hiPSCs was also deter-
mined based quantification of gene transcripts unique
for pluripotent cells: OCT4 and NANOG (Figure 4). Gene
expression profiles were determined by qRTPCR followedFigure 3 Flow cytometry of autologous human induced pluripotent s
were labeled with the antibodies highlighting the hallmark biomarkers: A: ant
in the spectra between the patients was addressed by calculating the full widby electrophoresis of amplicons, and digital image acquisi-
tion. Quantification of pixel densities in all lanes facilitated
quantification of gene expression, verification of amplifica-
tion specificity, and exclusion of possible mispriming. The
assays were performed as pairs: original PBMCs (Figure 4
2,4,6,8,10,12) before reprogramming and corresponding
autologous hiPSCs for every patient (Figure 4 1,3,5,7,9,11).
All samples were run in triplicates. As shown, genes
OCT4 and NANOG were not expressed in PBMCs, but
were strongly expressed in autologous hiPSCs.
Pluripotency of autologous hiPSCs was also validated by
their ability to form embryoid bodies (EBs), which differen-
tiated into the three main germ layers with the increasing
levels of lineage specific genes, while the hESCs and the
PBMCs served as the controls (Figure 5). The EBs were la-
beled with the synthetic antibodies targeting myosin heavytem cells. Autologous human induced pluripotent stem cells (ahiPSCs)
i-SSEA-3; B: anti-SSEA-4; C: anti-TRA-1-60; D: anti-TRA-1-81. The variability
th at half maximum (FWHM) and superimposing over the spectrum.
Figure 4 Electrophoresis of reverse transcribed and amplified ahiPSCs pluripotency genes’ transcripts. RNA was extracted from the
ahiPSCs and PBMCs, reverse transcribed to cDNA, and amplified. A. Amplicons were electrophoresed and imaged. B. The lanes were quantified.
Amplicons on the lanes: 1–4, 3–8, 9–12 for the patients C001-C003 respectively; 13–14, 16 standards; 15 no primers. The amplicons of ahiPSCs on
the lanes: 1,3,5,7,9,11 and of PBMCs on the lanes: 2,4,6,8,10,12; OCT4: lanes 1–2, 5–6, 9–10, NANOG: lanes 3–4, 7–8, 11–12.
Figure 5 Differentiation to embryoid bodies from ahiPSCs. The ahiPSCs’ demonstrated by their ability to grow, while aggregating, into
embryoid bodies (EB) and to differentiate into three germ layers with the human embryonic stem cells (hESCs, H1, H9) and the PBMCs included
as the controls. It was determined by labeling with superparamagnetic antibodies and measuring relaxivity by NMRS and validated by EDXS,
while normalized against total amount of protein. Biomarkers: A: myosin heavy chains (MHC); B: neurofilamentous proteins (NF); C: cytokeratins
(CK); D: Adrenergic β1 receptor (AdrR); E: Acetylcholine receptor (AChR); F: platelet endothelial cell adhesion molecules (PECAM).
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cytokeratins (Figure 5C), adrenergic β1 receptor (Figure 5D),
acetylcholine receptor (Figure 5E), and platelet endothelial
cell adhesion molecules (Figure 5F). Each of the antibodies
was modified with superparamagnetic, elemental tags.
This feature makes the quantification of the labeling
non-destructive and possible on living cells. This also
opens the possibilities for monitoring of the processes of
differentiation in vivo. Furthermore, the measurements
were confirmed with energy dispersive x-ray spectroscopy
(EDXS) in situ. Spectral separation facilitated simultan-
eous measurements of all three biomarkers in each of the
EBs. These measurements finally confirmed solid pluri-
potency of the generated autologous hiPSCs. Moreover,
revealing cell surface display of the receptors transmitting
the functional stimuli and the adhesion molecules respon-
sible for interactions with other cells affirmed that the
generated cells carry a potential for integrating with the
functioning myocardium of the host (study in progress).
Proliferation and differentiation of the cells in the
embryoid bodies were studied by measuring incorporation
of bromodeoxyuridine (BrdU) (indicator of proliferation)
and labeling of cardiac myosin heavy chains (MHC)
(Figure 6A). The data indicating progressing differentiation
were further supported by the decisive increase in the
number of EBs (Figure 6B). The progressing differenti-
ation was associated with suppression of the pluripotency
genes – in particular NANOG (Figure 6C).
Recruitment and retention of pluripotent stem cells to
infarcted myocardial sarcomeres
Efficacy of the htAbs’ to recruit and retain human autolo-
gous pluripotent induced stem cells (autologous hiPSCs)
to infarcted myocardium was assayed in the in vitro modelFigure 6 Proliferation and differentiation rates. A. Proliferation rates of
cardiomyocytes, for 12 days and 61 days, were determined by ratios of bro
normalized against all cells. B. Progressing differentiation was determined b
the hESCs and ahiPSCs. C. Progressing differentiation associated with suppr
initiated from the hESCs and the ahiPSCs after 1 day (hESC 1d and ahiPSC
undifferentiated hESCs and ahiPSCs (undif hESC and undif ahiPSC) as well a
was accepted for P < .05.and quantified (Figure 7). In these assays, autologous
hiPSCs, hESCs, or PBMCs, were injected into buffers,
which were circulating through the chamber containing
cardiac tissues.
Recruitment of autologous hiPSCs to infarcted myocar-
dium was quantified by counting numbers of the attached
cells (Figure 7A). These numbers were determined by
changes in relaxation times caused by presence of super-
paramagnetic tags and registered by NMRS. Alternatively,
these numbers were also calculated by changes in scintilla-
tion counts caused by elemental tags and registered by
EDXS or XRFS. The cell counts were normalized per unit
of cardiac tissue mass. All measurements were performed
in triplicates for each patient and were representative for
all studied, as documented. Numbers of the recruited cells
were much higher in assays, in which administration of the
htAbs preceded administration of pluripotent stem cells.
Numbers of the anchored autologous hiPSCs were compar-
able to hESCs, which displayed the same biomarkers of
pluripotency and served as positive controls. The htAbs
had no effect on adhesion of PBMCs, which did not display
the biomarkers of pluripotency and served as negative
controls. The htAbs did not affect attachment of the
autologous hiPSCs to endothelial monolayers.
Retention of the anchored cells was quantified by count-
ing numbers of the cells, which remained detected onto
the sarcomeres over different periods of time (Figure 7B).
Quantifications were conducted as described above. All
pluripotent stem cells, autologous hiPSCs and hESCs, an-
chored to the sarcomeres with the htAbs, were efficiently
retained with minimal losses. As there was practically no
recruitment of PBMCs, so was no retention.
Specificity of the htAbs, in recruiting the ahiPSCs to
the sarcomeres, was promoted by the htAbs’ domainsthe ahiPSCs, in the embryoid bodies differentiating towards
modeoxyuridine (BrdU) to cardiac myosin heavy chains (MHC)
y counting the increasing number of embryoid bodies initiated from
ession of NANOG expression - the key pluripotency gene in the EBs
1d) versus 60 days (hESC 60d and ahiPSC 60d), while compared to the
s the PBMCs (undif PBMC 1d and undif 60d). The statistical significance
Figure 7 Recruitment and retention of pluripotent stem cells to infarcted myocardium in vitro. The autologous human induced
pluripotent stem cells (ahiPSCs) were anchored to infarcted myocardia with the aid of heterospecific, tetravalent antibodies (htAbs). The data
were validated with EDXS. (A) Efficacy of the htAbs to anchor ahiPSCs to cardiac muscle sarcomeres (ahiPSCs sarc) or endothelium (ahiPSCs endo). The
htAbs were constructed from anti-SSEA-4, anti-TRA-1-60, anti- myosin, anti-α-actinin. For comparison, the efficacy of the htAbs to anchor the human
cultured embryonic stem cells H1, H9 to the sarcomeres (hESC sarc) and to endothelium (hESC endo) and the PBMCs to the sarcomeres (hPBMC sarc)
and endothelium (hPBMC endo) was determined. The measurements for each patient were conducted in triplicates. The data presented here are
representative to all the samples studied. The statistical difference was accepted at P < .0003. (B) Retention of the anchored ahiPSCs onto the
sarcomeres upon the day 1 of administration (ahiPSC sarc 1 d) was compared with that after 12 days (ahiPSC sarc 12 d). For reference, retention of the
hESCs and the hPBMCs were quantified at the same time intervals. (C) Specificity of the htAbs to anchor the ahiPSCs to sarcomeres (ahiPSCs sarc)
was tested by blocking the antigens on the ahiPSCs with non-specific tetravalent antibodies (anti-EGFRvIII, anti-EGFRvIV, anti-CEA, anti-PSMA)
(ahiPSC sarc nsAb block) and with monospecific antibodies (anti-SSEA-4, anti-SSEA-3, anti-TRA-1-60, anti-TRA-1-81) (ahiPSCs sarc mAb block), or
by omitting antibodies altogether (ahiPSCs no Ab). Blocking these biomarkers almost entirely eliminated anchoring of the ahiPSCs to the sarcomeres.
The statistical significance was accepted at P < .0003. (D) Specificity of the htAbs to anchor the ahiPSCs onto the sarcomeres (ahiPSCs sarc) was
measured by blocking antigens on the human cardiac muscle sarcomeres with non-specific tetravalent antibodies (anti-EGFRvIII, anti-EGFRvIV,
anti-CEA, anti-PSMA) (ahiPSCs sarc nsAb block), with the monospecific antibodies (anti-myosin, anti-actin, anti-α-actinin, anti-titin) (ahiPSCs mAb block),
or by omitting antibodies altogether (ahiPSCs no Ab). Blocking of these sarcomeric molecules almost entirely eliminated anchoring of the ahiPSCs to
the sarcomeres. The statistical significance was accepted at P < 0.0003.
Malecki et al. Molecular and Cellular Therapies 2014, 2:13 Page 11 of 16
http://www.molcelltherapies.com/content/2/1/13anti-SSEA-3, anti-SSEA-4, anti-TRA-1-60, or anti-TRA-
1-81 (Figure 7C). Introduction of the monospecific anti-
bodies blocking these biomarkers onto the ahiPSCs and
hESCs resulted in significant reduction in the numbers
of the anchored cells. They practically abrogated anchorage
of the autologous hiPSCs. The non-specific antibodies did
not enhance recruitment of these cells to the sarcomeres.
On the other hand, specificity of the htAbs for recruiting
the ahiPSCs to the sarcomeres relied onto their domains
targeting the sarcomeric proteins: anti-myosin, anti-actin,
anti-α-actinin, and anti-titin (Figure 7D). Monospecific
antibodies and free circulating sarcomeric proteins were
used to block antigens on sarcomeres and binding sites of
the htAbs (respectively). Blocking the domains on the sarco-
meres practically prevented anchoring the htAbs onto them
and eliminated their bridging functions for the ahiPSCs.
Cardiomyogenesis of autologous human induced
pluripotent stem cells
Cardiomyogenesis of the stem cells, which were retained
onto the myocardial sarcomeres, was initiated by BMP,
NAM, and Wnt3. Outcomes of this directed differentiation
were determined based upon quantification of gene
transcripts (Figure 8). At the selected time intervals, the
cells were harvested for mRNA extraction. That followed
by quantitative reverse transcription and polymerase chain
reaction (qRTPCR). All the patients' samples (C001-C006), positive controls (hESCs: H1, H9), and negative
control (PBMCs: C001-C006) were run in triplicates and
the data were merged. During the time course of differen-
tiation, the gene expression profiles were changing. Already
within 5 days from the first administration of those differ-
entiating factors, the changes were apparent.
Quantities of transcripts for genes characteristic for
pluripotency: OCT4 and NANOG were decreasing.
Simultaneously, quantities of transcripts for genes unique
for myogenesis: GATA4 and MEF-2c were increasing.
These trends continued throughout entire periods studied.
Identical changes occurred in the hESCs exposed to the
same factors. These changes did not occur in the PBMCs.
Functional tests of contractile apparatus and adrenergic
receptors in cardiomyocytes developing from the ahiPSCs
The autologous human induced pluripotent stem cells
(ahiPSCs) were capable of differentiating into the fully
functional cardiomyocytes. That was determined by steadily
increasing numbers of the adrenergic β1 receptors displayed
on the differentiating cells (Figure 9A). The displayed recep-
tors were clearly fully functional as the administration of
the Isoprenaline resulted in the significant (almost 50%)
increase in the beating rate (Figure 9B). Therefore, in
addition to the full functional maturity of the myocytes
generated from the ahiPSCs validated by rhythmic con-
tractions – “beating”, the functional maturity of the
Figure 8 Cardiomyogenesis of pluripotent induced stem cells. Differentiation towards myocardial lineage was quantified by measuring levels
of gene expression by qRTPCR in human autologous pluripotent induced stem cells (ahiPSCs) (patients C001-C006), human embryonic stem cells
(hESCs) (lines H1, H9) – positive control), peripheral blood mononuclear cells (PBMCs) (patients C001-C006) - negative control. In the three time
points on the days 1, 5, and 12, the levels of transcripts for: pluripotency genes NANOG (A) and OCT4 (B) decreased, while the levels of transcripts
for early myogenesis genes GATA4 (C) and MEF-2c (D) increased. The statistical significance was accepted for P < .05.
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nomena were demonstrated by reverse transcription of
mRNA into cDNA, nested qRTPCR for the adrenergic β1
receptors, and electrophoresis of amplicons (Figure 9C). It
revealed the robust expression of the genes for the adren-
ergic β1 receptors.
Discussion
Herein, we report the proof of concept for reprogram-
ming of the patients’ blood mononuclear cells into au-
tologous stem cells, recruiting these stem cells to
infarcted myocardium with bioengineered antibodies
in vitro, and initiating their cardiomyogenesis in situ.
Below, we discuss several aspects of this novel, but
complex therapeutic strategy.
In this study, the patients’ own peripheral blood mono-
nuclear cells were acquired by blood draws. This is surely
the least traumatic way for patients to source stem cells for
regenerative therapy. In particular, if it is compared to other
means of cell acquisition by bone marrow aspiration, car-
diac biopsy, or skin excision. Moreover, thinking prospect-
ively about streamlining of this experience into clinical
trials, using autologous stem cells reduces risks of potentialFigure 9 Functional tests of contractile apparatus and adrenergic rec
cardiomyocytes was determined by qRTPCR of the transcripts for adrenerg
PBMCs served as the controls. B. Functional maturity of the AdrRs was qua
with increasing concentrations of Isoprenaline - adrenergic β1 agonist. C. E
(lane 4) and ahiPSCs (lane 3) was compared to the cardiac tissue (lane 2) a
the PBMCs served as the controls (lane 6).immune responses to therapeutically delivered cells or side
effects due to immuno-suppression. Advantages of reduced
risks of immunological response expand also onto other
elements of this strategy. All components of cell selection,
culture, and antibody engineering were of human origin,
which reduced potential risks of immunological response
triggered by toll like receptors. In particular, recombinant
proteins produced in mice, yeast, or bacteria are well
known to trigger such rapid responses. Furthermore,
our in vitro model of myocardial infarction therapy con-
sisted of all human constituents. This is one of the most
important factors in conducting laboratory research in
preparation for clinical trials. It is well established that
human pluripotent stem cells have different expression
profiles, than those from non-humans. Stage-specific em-
bryonic antigen 1 (SSEA-1), which is displayed on mouse
embryonic stem cells is absent on early human embryonic
stem cells, but is expressed only upon differentiation, is one
of many examples. Ignoring these facts results in only less
than 0.4% of laboratory research is streamlined to clinical
trials [11,12]. The presented model has its drawbacks
in studying long-term changes, which occur during
healing processes in vivo. These processes may includeeptors in developing cardiomyocytes. A. Differentiation of
ic β1 (AdrR) receptors normalized by ratios with GAPDH over time. The
ntified by measuring the beat rate in embryoid bodies after treatment
xpression of adrenergic β1 (AdrR) receptors in the differentiating hESCs
nd standard (lane 1), while the undifferentiated ahiPSCs (lane 5) and
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transitions, mounting immune response, infiltration with
immune cells, or continuous influx of cytokines. Never-
theless, refining this fully human in vitro model, which we
have developed, should improve defining correct starting
conditions for myocardial infarction stem cell therapy.
Initial successes in inducing pluripotency of human fibro-
blasts were attained through delivery of coding sequences
for four transcription factors by retroviral vectors. Unfortu-
nately, both, reprogramming factors and retroviral vectors,
are potentially cancerogenic. Improvements of those ori-
ginal protocols involved switching to non-viral vectors, re-
ducing numbers of transcription factors, inclusion of small
molecules. In particular, some small molecules may reduce
thresholds for activation of genes inducing pluripotency.
These include valproic acid (VPA) inhibiting histone dea-
cetylase (HDAC), 5-azacytidine (AZA) inhibiting DNA
methyltransferase, or E-616452 inhibiting Tgf-β signaling.
Although, these small molecules may work to specific-
ally bind to and disable targeted biomolecules, the nat-
ural transcription factors not only activate pluripotency
cascades, but also repress differentiation signaling. Ac-
cordingly, genomic profiling revealed differences be-
tween pluripotent cells reprogrammed from adult cells
by various protocols, which often explained low effica-
cies and inconsistencies in abilities of these cells to dif-
ferentiate. These data prompted us to design pluripotency
inducing protocols including six transgenes, which
were enhanced by small molecules. We also designed
the vectors to host chelating domains saturated with
atoms of exogenous metals. This approach facilitated
not only efficient induction of pluripotency, but also
easy monitoring of the transfected stem cells’ kinetics
by XRFS or NMRS [10].
The most serious concern for potential streamlining of
the pluripotent stem cells into clinics is the fact that these
cells carry inherent risks of giving raise to tumors [41-45].
In fact, one of the cells' pluripotency tests is their ability
to form teratomas in nude mice. Clinical cases of tumors
grown in hearts as outcomes of stray stem cell therapy were
reported [42]. The main strategies have been developed
aimed at reducing the risks of iatrogenic tumorigenesis
by human induced pluripotent stem cells, as recently
reviewed [41,44,50]. First, antibodies against the bio-
markers displayed on surfaces of undifferentiated cells
facilitate sorting them out from populations of differ-
entiating cells. Some of these antibodies demonstrated
toxic effects towards undifferentiated stem cells. These
effects can be further enhanced by linking toxins to
those antibodies on an identical manner as in cancer
immunotherapy. Second, differentiated cells after being
engineered with reporter genes facilitate sorting them in.
Only the precursors of the desired lineages are included
into the further steps. The third approach relies upondelivery of the cell suicide inducing genes on a manner
identical to cancer suicide gene therapy [46-50].
Retention of pluripotent stem cells to injured zones was
defined as the most critical problem for progressing stem
cell therapy [5]. Herein, we addressed this problem by
bioengineering heterospecific antibodies serving as bridges
between stem cells and regenerated myocardium. In the
strategy, stem cell recruitment and retention are contin-
gent upon specificity of bioengineered antibodies, as
well as strong display of biomarkers by pluripotent stem
cells and preservation of antigenicity by sarcomeric mole-
cules. High specificity of the bioengineered antibodies has
been attained by gene shuffling and in vitro evolution as
demonstrated by immunoblotting, multiphoton imaging,
NMRS, EDXS, and flow cytometry. Strong and sustained
display of biomarkers on stem cells is contingent upon
their viability. Therefore, we committed rounds of deple-
tion of apoptotic and dying cells in addition to rounds of
positive selection of cells displaying biomarkers of pluripo-
tency [11,12]. Equally important was securing solid matrix
for heterospecific antibodies to attach to. Preservation of
architecture and antigenicity of sarcomeres was supported
by using the University of Wisconsin Solution. It could be
further enhanced by introducing heterospecific antibodies
cross-linking sarcomeric proteins, thus to enforce retention
of scaffolds. Nevertheless, we are aware of potential risks
of stray heterospecific antibodies. They have to be cleared
from circulation, so that they cannot cluster multiple cells
and create microemboli.
The ultimate goal of this endeavor was to generate new
cardiomyocytes in situ. Therefore, we designed this project,
so that the factors directing differentiation would simulate
molecular and temporal patterns, which occurr during
human embryogenesis. They would be compatible with
human signaling pathways and suitable for future ap-
plication in vivo. That was our preference, rather than
relying upon small synthetic molecules like KY02111. Bone
morphogenetic proteins 2/4 (BMP) belong to transforming
growth factor-β super family, which upon binding to their
receptors, trigger SMAD signaling pathways. This leads to
formation of mesoderm and progressing through differenti-
ation with expression of GATA4, Mcef2c, and Serf. Wnt3
binds to frizzled receptors, while starting signaling pathway,
which is modulated by β-catenin. That leads also to meso-
derm formation, but later to expression of Nkx2-5, Isl1, and
Baf60c. These specific factors are further enhanced by
inclusion of NAM. In this study, we are primarily focused
on initiating cardiomyogenesis. Therefore, the media
contained not only supplements stimulating cardiomyo-
genesis, but also blocking other routes of differentiation
by antibodies to VEGFR and PDGFR, which otherwise
could trigger differentiation towards endothelia and smooth
muscle (respectively). Ahead of us, is to define temporal
and molecular patterns, which are not only initiating, but
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formation of gap junctions and integration with healthy
myocardium.
From the cardiothoracic surgeons’ point of view, this ap-
proach of stem cell therapy of infarcted myocardium should
be most effective, if applied at early periods of time after
infarction. This would be best at the time of or immediately
after revascularization [3,4]. At those times, the htAbs
would have best access to the exposed sarcomeric pro-
teins. With passing times, healing scars create barriers
for antibodies and cells. Moreover, molecular components
of scarred tissue are different, than those at early stages
of infarction. In particular, production of collagen creates
different matrix for stem cells to interact with. Influx of
cytokines also affects stem cells. Therefore, specificity of
bridge antibodies and repertoire of cardiomyogenesis
stimulating molecules may have to be adjusted in relation
to changing with time healing processes in situ. This strat-
egy will have to be refined even further to take into ac-
count patients’ medical histories and genomic profiles.
From hospital pharmacists’ point of view, developed
heterospecific antibody biotechnology is very robust.
The assembled htAbs have solid stability with a long
shelf due to high affinity constants between components
(biotin-avidin bonds) [15,16]. As such, this biotechnology
can be easily adapted to GMP standards within cardio-
thoracic surgery departments. Moreover, this biotech-
nology is very flexible. Therefore, if new biomarkers of
autologous stem cells are discovered, then specific anti-
bodies can be selected from the human antibody library
and easily incorporated into this antibody platform; thus
into this therapeutic strategy.
For the purpose of our studies on regeneration, we have
developed means to quantify processes not only in vitro
in research labs, but also in vivo in clinical settings. The
keystones of this approach are the superparamagnetic
antibodies, which we designed, synthesized, and thoroughly
characterized previously [14-18]. The main advantage
of these antibodies is that they facilitate precise quanti-
fication of these processes not only in vitro by NMRS,
but also they are directly applicable in vivo with MRI.
Moreover, they are safe to use in a teaching institutions
setting. The acquired data are validated with EDXS and
XRFS. Finally, the data are instantly available and can be
used for adjusting the protocols. An alternative approach
would involve using antibodies charged with radionuclides.
After screening by scintillation counting, it could be
extrapolated to PET, SPECT, or Gamma. However, this
option requires special infrastructure and special training
of the investigators, as well as greater potential risks and
side effects for patients and staff and students. An alterna-
tive approach would involve fluorescent derivative of anti-
bodies. However, this approach is so far only limited to
studies on cells or sections with a very limited possibilityfor extrapolation into clinics due to hard to deconvolve
scattering of light by the tissue. Therefore, in this study
we relied primarily on the synthetic antibodies tagged
with atoms of the exogenous elements rendering them
super-paramagentic.
In this study, we demonstrated that we can significantly
enhance recruitment and retention of the autologous
human induced pluripotent stem cells (ahiPSCs) to the
infarcted myocardium with the aid of the heterospecific
tetravalent antibodies (htAbs). We decided to choose
this route with potential streamlining into the clinics.
Moreover, we did so in lieu of reports of rejection of
heterologous transplants. Nevertheless, allogeneic sources
may be considered.
We have completed this work on the ahiPSCs. While
we improved the recruitment and retention of the stem
cells, the first and foremost problem in using any pluri-
potent stem cells in clinics is the risk of their inherent
tumorigenicity. While initial screening prior to implant-
ation may facilitate elimination of the tumorigenic clones,
the strategies allowing us to monitor processes of differ-
entiation in vivo after implantation of therapeutic cells,
as well as to eliminate instantly any cells heading towards
tumorigenic transformation are really necessary as recently
reviewed [46-50]. In addition, two strategies may further
enhance safety of the stem cell therapy, while relying on the
enhanced stem cell recruitment biotechnology presented
herein: direct trans-differentiation and induction of pro-
genitors. The direct trans-differentiation relies upon lineage
reprogramming with the defined factors [10,28-38]. There-
fore, the pluripotency stage is entirely eliminated. In this
strategy, the htAbs’ domains anchoring onto the infarcted
myocardium sarcomeres remain the same, but those do-
mains anchoring therapeutic cells are modified to tag the
cell surface displayed biomarkers. This strategy facilitated
significantly enhanced recruitment and retention of the
clones of bone marrow cells expressing CD34, CD117,
and CD133 to the sarcomeres of the infarcted myocardia
[10]. Thereafter, the differentiation is propelled by the
homing environment and additional factors inducing
the directed lineage reprogramming. Yet another strat-
egy relies upon reprogramming adult cells into human
induced pluripotent stem cells followed by their differ-
entiation towards desired lineage progenitors [22-24].
For the purpose of this strategy, the htAbs’ domains
anchoring onto the infarcted myocardium sarcomeres
remain the same, but those domains anchoring the pro-
genitors are modified to the specific cell surface display
profiles. We currently pursue both routes.
Conclusion
The proof of concept has been attained in vitro, for
reprogramming the patients’ blood mononuclear cells
into human, autologous, pluripotent stem cells, recruiting
Malecki et al. Molecular and Cellular Therapies 2014, 2:13 Page 15 of 16
http://www.molcelltherapies.com/content/2/1/13these stem cells to infarcted myocardium, and initiating
their cardiomyogenesis. This novel strategy is ready to
support the ongoing clinical trials in cardiothoracic sur-
gery aimed at regeneration of infarcted myocardium.
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